Stock Quote

ACOR (Common Stock) $ 32.58 +0.29 (+0.9%) Volume: 142,812 MORE August 29, 2014

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *






Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.

Acorda markets three FDA-approved therapies including:  AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg,  a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and Qutenza® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia.  AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.

Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure.

Stock Chart

Financials

Date Filing Description Download
08/29/14 4 Statement of Changes in Beneficial Ownership
08/26/14 CT ORDER Confidential Treatment Order
08/07/14 10-Q Quarterly Report
08/07/14 CT ORDER Confidential Treatment Order